The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MBNKF, XENT, BUD and TEVA

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Metro Bank PLC (OTCMKTS: MBNKF)
Class Period: March 6, 2018 to May 1, 2019
Lead Plaintiff Deadline: July 29, 2019

The lawsuit alleges that Metro Bank PLC made materially false and/or misleading statements and/or failed to disclose that: (1) Metro Bank misclassified the risk terms of many of its loans; (2) accordingly, Metro Bank failed to maintain sufficient capital; (3) this conduct would lead to investigations by the PRA and FCA; (4) this conduct would also lead to the reduction of deposits at Metro Bank from larger commercial and partnership clients; and (5) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

Get additional information about the MBNKF lawsuit: http://www.kleinstocklaw.com/pslra-1/metro-bank-plc-loss-submission-form?wire=3 

Intersect ENT, Inc. (NASDAQGM: XENT)
Class Period: August 1, 2018 to May 6, 2019
Lead Plaintiff Deadline: July 15, 2019

Throughout the class period, Intersect ENT, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect’s sinus implant; (2) Intersect’s sales force would focus on ensuring reimbursement; (3) Intersect’s sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect’s SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants’ positive statements about Intersect’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Get additional information about the XENT lawsuit: http://www.kleinstocklaw.com/pslra-1/intersect-ent-inc-loss-submission-form?wire=3 

Anheuser-Busch Inbev Sa/Nv (NYSE: BUD)
Class Period: March 1, 2018 to October 24, 2018
Lead Plaintiff Deadline: August 20, 2019

According to the filed complaint, Defendants issued a steady stream of materially false and misleading reassurances about Anheuser Busch’s deleveraging efforts, cost cutting measures, EBITDA growth, the sufficiency of its liquidity and its debt maturity profile during the Class Period. These positive statements by Defendants created a false impression and materially misled investors about the Company’s finances, including the sustainability of Anheuser-Busch’s dividends. Once Defendants chose to speak about Anheuser-Busch’s finances, they had a duty to speak completely and truthfully, including speaking about those factors that were then having a material adverse effect on the Company’s deleveraging efforts.

Get additional information about the BUD lawsuit: http://www.kleinstocklaw.com/pslra-1/anheuser-busch-inbev-sa-nv-loss-submission-form?wire=3 

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
Class Period: on behalf of all persons or entities who purchased or otherwise acquired Teva American Depositary Shares (“ADS”) between August 4, 2017 and May 10, 2019
Lead Plaintiff Deadline: August 23, 2019

The lawsuit alleges Teva Pharmaceutical Industries Ltd. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.

Get additional information about the TEVA lawsuit: http://www.kleinstocklaw.com/pslra-1/teva-pharmaceutical-industries-ltd-loss-submission-form?wire=3 

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com